Drugs / Azilsartan

Trials 20 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT03434977 Feb → Mar 2018 Takeda Completed No outcome recorded
Phase 1 NCT03042299 Feb → Mar 2017 Takeda Completed No outcome recorded
Phase 1 NCT02786082 Nov 2016 → Aug 2017 hypertensive disorder Lee's Pharmaceutical Limited Completed No outcome recorded
Phase 23 trials
Phase 2 NCT01289132 Jul 2007 → Jul 2008 essential hypertension Takeda Completed No outcome recorded
Phase 2 NCT00759551 Aug 2004 → Jun 2005 essential hypertension Takeda Completed No outcome recorded
Phase 2 NCT00762736 Jul 2004 → Oct 2005 type 2 diabetes mellitus Takeda Completed No outcome recorded
Phase 39 trials
Phase 3 NCT04668157 May 2021 → Dec 2023 hypertensive disorder Takeda Completed No outcome recorded
Phase 3 NCT04606563 Oct 2020 → Apr 2022 COVID-19 University of British Columbia Terminated No outcome recorded
Phase 3 NCT02791438 Aug 2016 → Jun 2019 early onset hypertension Takeda Completed No outcome recorded
Phase 3 NCT02609490 Sep 2015 → Feb 2017 essential hypertension Lee's Pharmaceutical Limited Completed No outcome recorded
Phase 3 NCT02451150 Aug → Sep 2015 early onset hypertension Takeda Completed No outcome recorded
Phase 3 NCT02407210 Jan → Oct 2015 essential hypertension Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 3 NCT02277691 Nov 2014 → Apr 2016 essential hypertension Takeda Completed No outcome recorded
Phase 3 NCT01124656 Sep 2006 → May 2007 type 2 diabetes mellitus Takeda Terminated No outcome recorded
Phase 3 NCT00376181 Jun 2006 → May 2007 type 2 diabetes mellitus Takeda Terminated No outcome recorded
Phase 43 trials
Phase 4 NCT05841654 Jun 2023 → Jun 2025 atrial fibrillation, hypertensive disorder Beijing Tsinghua Chang Gung Hospital Unknown No outcome recorded
Phase 4 NCT02400775 Mar 2015 → Apr 2016 Takeda Withdrawn No outcome recorded
Phase 4 NCT02079805 Jun 2014 → Apr 2016 type 2 diabetes mellitus Takeda Completed No outcome recorded
Phase not applicable2 trials
NCT05753696 Apr 2023 → Oct 2024 diabetic kidney disease, hypertensive disorder, impaired renal function disease, proteinuria Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
NCT01762501 Dec 2012 → Dec 2013 essential hypertension Sogo Rinsho Médéfi Co., Ltd. Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT02235519 Comparator Jan 2014 → Jun 2015 hypertensive disorder, obesity disorder, type 2 diabetes mellitus Hospital General de México Dr. Eduardo Liceaga Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT01609959 Comparator Jun 2012 → Sep 2013 hypertensive disorder Nara Medical University Completed No outcome recorded
Phase not applicable1 trial
NCT07683585 Comparator Apr → Jul 2026 overdue coronary artery disorder, hypertensive disorder National Medical Research Center for Therapy and Preventive Medicine Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2014-06-18 Takeda Zacras ® Combination Tablets LD and Zacras ® Combination Tablets HD, Fixed-Dose Combination of Azilsartan and Amlodipine, and Azilva ® Tablets 10mg, Treatment for Hypertension, are Now Available in Japan takeda.com

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 23 sources stand behind the page.

FieldValueCited text
Known as Azilsartan “This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ).” PMID 29235365 Dec 2017
20

“A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation” NCT03434977

NCT01124656

NCT02400775

NCT01609959

NCT02451150

NCT02791438

NCT02609490

NCT01289132

NCT02235519

NCT07683585

NCT01762501

NCT00762736

NCT00376181

NCT02079805

NCT05753696

NCT05841654

NCT00759551

NCT02407210

NCT02786082

NCT04606563

Known as AZL “This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ).” PMID 29235365 Dec 2017
Known as TAK-536 “AD-4833-536 is a combination of AD-4833 (pioglitazone) and TAK-536 (azilsartan).” NCT01124656
3

NCT03434977

NCT04668157

NCT03042299

Action Inhibit “TAK-536 (azilsartan) is a synthetic angiotensin II type-1 receptor antagonist” NCT00759551
Route Oral “Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily” NCT00376181